MetaCap

Allogene Therapeutics (ALLO) vs Autolus Therapeutics (AUTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed Allogene Therapeutics (ALLO) over the past year, losing 26.2% versus a loss of 49.0%. Over five years, AUTL leads with a -85.5% price change compared with -96.5% for ALLO. Autolus Therapeutics is the larger company by market cap ($241.7 million vs $217.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%AUTL-26.24%
+159%+50%-59%
Nov 21, 20251 yearNov 20, 2026
ALLO-96.66%AUTL-85.41%
+21%-41%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus AUTL key metrics
MetricALLOAUTL
Share price$0.6277$0.9073
Market cap$217.48M$241.65M
1-day change-5.88%-7.38%
YTD return-54.18%-54.41%
1-year return-48.97%-26.24%
5-year return-96.51%-85.51%
EPS (TTM)$-0.61$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$75.39M
Revenue growth (YoY)-100.00%+644.94%
Net income (latest FY)$-190.89M$-287.53M
Gross margin—-27.83%
Operating margin—-358.87%
Net margin—-381.40%
52-week high$4.46$2.58
52-week low$0.6192$0.896
Distance from 52-week high-85.93%-64.83%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1333.81%+821.42%
Average volume7.69M2.07M
Shares outstanding346.47M266.34M
Employees150752
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AUTL has outperformed ALLO by 22.7 percentage points over the past year.
  • Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs -100.00%).

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

ALLO vs AUTL FAQ

Which is bigger, Allogene Therapeutics or Autolus Therapeutics?

Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $217.48M for Allogene Therapeutics (ALLO).

Which stock has performed better over the past year, ALLO or AUTL?

AUTL returned -26.24% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Autolus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons